How often does infliximab need to be administered?

Infliximab(Infliximab) is a monoclonal antibody directed against tumor necrosis factor alpha (TNF-α). It is widely used in the treatment of a variety of autoimmune diseases, includingCrohn's disease (CD), ulcerative colitis, rheumatoid arthritis (RA), psoriasis, active psoriatic arthritis(PA), ankylosing spondylitis, etc. The drug is administered by intravenous infusion, and the dosing interval needs to be adjusted according to the patient's disease type, degree of disease control, and the individualized plan formulated by the doctor.

Generally speaking, in the early stage of treatment, the standard induction phase administration schedule of infliximab is one infusion at 0, 2 and 6 weeks. The purpose of this phase is to quickly control the inflammatory response and establish a stable blood concentration. After entering the maintenance treatment phase, most patients receive injections every 8 weeks to maintain long-term remission of the disease.

However, the exact frequency of dosing is not set in stone. If the patient responds well to treatment and the condition is stable for a long time, the doctor may extend the dosing interval; conversely, if the symptom control is not ideal or relapses occur frequently, the interval may be shortened to every 6 weeks or less, and other immunosuppressive drugs may even be considered to enhance the efficacy.

It is worth noting that infliximab is a protein biological agent, and the body may produce anti-drug antibodies, which will affect the persistence of the drug effect. In this case, doctors may adjust the dose or use a combination of immunomodulators to prolong the effectiveness of the drug. During the entire treatment process, patients need to undergo regular inflammatory indicators and immune-related examinations to evaluate efficacy and safety.

Therefore, there is no fixed injection cycle for infliximabIt is usually once every 6 to 8 weeks, but it still needs to be flexibly adjusted based on clinical manifestations and individual differences. Standardized treatment management and good compliance are the keys to ensuring the lasting efficacy of infliximab.

Reference materials:https://www.drugs.com/infliximab.html